By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Polyenes > Amphotericin b liposomal > Amphotericin B Liposomal Dosage
Polyenes
https://themeditary.com/dosage-information/amphotericin-b-liposomal-dosage-10748.html

Amphotericin B Liposomal Dosage

Drug Detail:Amphotericin b liposomal (Amphotericin b liposomal [ am-foe-ter-i-sin-b-lye-poe-soe-mal ])

Drug Class: Polyenes

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Aspergillosis - Invasive

3 to 5 mg/kg/day IV over 120 minutes

Comments:

  • Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.

Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.

Usual Adult Dose for Candidemia

3 to 5 mg/kg/day IV over 120 minutes

Comments:

  • Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.

Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.

Usual Adult Dose for Cryptococcosis

3 to 5 mg/kg/day IV over 120 minutes

Comments:

  • Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.

Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.

Usual Adult Dose for Febrile Neutropenia

3 mg/kg/day IV over 120 minutes

Comments:

  • Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.

Use: Empiric therapy for presumed fungal infection in febrile, neutropenic patients.

Usual Adult Dose for Cryptococcal Meningitis - Immunosuppressed Host

6 mg/kg/day IV over 120 minutes

Comments:

  • Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.

Use: Treatment of Cryptococcal meningitis in HIV infected patients

Usual Adult Dose for Leishmaniasis

Immunocompetent patients: 3 mg/kg/day IV on days 1 through 5, and days 14 and 21

  • Infuse over 120 minutes.
  • If parasitic clearance is not achieved, a repeat course may be useful.

Immunocompromised patients: 4 mg/kg/day IV on days 1 through 5, and days 10, 17, 24, 31 and 38
  • Infuse over 120 minutes.
  • If parasitic clearance is not achieved or relapse occurs, seek expert advice regarding further treatment.

Comments:
  • Relapse rates after initial clearance of parasites were high in immunocompromised patients treated with this drug.
  • Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.

Use: Treatment of visceral leishmaniasis

Usual Adult Dose for Coccidioidomycosis

Severe, non-meningeal infection: 3 to 5 mg/kg/day IV
Duration of therapy: Until clinical improvement

  • Follow with triazole

Use: Coccidioidomycosis

Usual Adult Dose for Blastomycosis

Moderate to severe pulmonary blastomycosis: 3 to 5 mg/kg/day IV
Duration of therapy: 1 to 2 weeks or until improvement is noted

  • Follow with itraconazole

Moderate to severe extrapulmonary blastomycosis: 3 to 5 mg/kg/day IV
Duration of therapy: 1 to 2 weeks or until improvement is noted
  • Follow with itraconazole

CNS blastomycosis: 5 mg/kg/day IV
Duration of therapy: 4 to 6 weeks
  • Follow with an oral azole

Blastomycosis, immunosuppressed patient: 3 to 5 mg/kg/day IV
Duration of therapy: 1 to 2 weeks or until improvement is noted
  • Follow with itraconazole

Blastomycosis during pregnancy: 3 to 5 mg/kg/day IV
Duration of therapy: 1 to 2 weeks or until improvement is noted
  • Avoid azoles because of possible teratogenicity


Use: Blastomycosis

Usual Pediatric Dose for Aspergillosis - Invasive

1 month and older:
3 to 5 mg/kg/day IV over 120 minutes

Comments:

  • Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.

Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.

Usual Pediatric Dose for Candidemia

1 month and older:
3 to 5 mg/kg/day IV over 120 minutes

Comments:

  • Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.

Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.

Usual Pediatric Dose for Cryptococcosis

1 month and older:
3 to 5 mg/kg/day IV over 120 minutes

Comments:

  • Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.

Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.

Usual Pediatric Dose for Febrile Neutropenia

1 month or older:
3 mg/kg/day IV over 120 minutes

Comments:

  • Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.

Use: Empiric therapy for presumed fungal infection in febrile, neutropenic patients.

Usual Pediatric Dose for Cryptococcal Meningitis - Immunosuppressed Host

1 month or older:
6 mg/kg/day IV over 120 minutes

Comments:

  • Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.

Use: Treatment of Cryptococcal meningitis in HIV infected patients

Usual Pediatric Dose for Leishmaniasis

1 month or older:
Immunocompetent patients: 3 mg/kg/day IV on days 1 through 5, and days 14 and 21

  • Infuse over 120 minutes.
  • If parasitic clearance is not achieved, a repeat course may be useful.

Immunocompromised patients: 4 mg/kg/day IV on days 1 through 5, and days 10, 17, 24, 31 and 38
  • Infuse over 120 minutes.
  • If parasitic clearance is not achieved or relapse occurs, seek expert advice regarding further treatment.

Comments:
  • Relapse rates after initial clearance of parasites were high in immunocompromised patients treated with this drug.
  • Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.

Use: Treatment of visceral leishmaniasis

Renal Dose Adjustments

Data not available

  • This drug has been successfully administered to patients with pre-existing renal impairment.

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 1 month.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

  • Hemodialysis or peritoneal dialysis do not appear to significantly affect elimination of this drug.

Other Comments

Administration advice:

  • Administer over approximately 120 minutes using a controlled infusion device.
  • Administration time can be reduced to 60 minutes if treatment is well tolerated.
  • Administration time can be increased if the patient experiences discomfort.
  • An inline filter may be used if mean pore diameter is not less than 1 micron.
  • Existing IV line must be flushed with 5% dextrose prior to administration; if line cannot be flushed with 5% dextrose, administer through a separate line.

Storage requirements:
  • Store at temperatures up to 77F.

Reconstitution/preparation techniques:
  • The manufacturer product information should be consulted.


IV compatibility:
  • Dilute with 5% dextrose.
  • Not compatible with saline.
  • Do not mix with other drugs.

General:
  • Carefully observe patients during the initial dosing period.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by